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Background: Breast-conserving surgery (BCS) followed by radiotherapy is generally the preferred treatment for
women diagnosed with early stage breast cancer. This study aimed to investigate the proportion of patients who
receive BCS versus mastectomy and post-BCS radiotherapy, and explore factors associated with receipt of these
treatments in Alberta, Canada.
Methods: A retrospective population-based study was conducted that including all patients surgically treated with
stage I-III breast cancer diagnosed in Alberta from 2002–2010. Clinical characteristics, treatment information and
patient age at diagnosis were collected from the Alberta Cancer Registry. Log binomial multiple regression was
used to calculate stage-specific relative risk estimates of receiving BCS and post-BCS radiotherapy.
Results: Of the 14 646 patients included in the study, 44% received BCS, and of those, 88% received post-BCS
radiotherapy. The adjusted relative risk of BCS was highest in Calgary and lowest in Central Alberta for all disease
stages. Relative to surgeries performed in Calgary, those performed in Central Alberta were significantly less likely
to be BCS for stage I (RR = 0.65; 95% 0.57, 0.72), II (RR = 0.58; 95% 0.49, 0.68), and III (RR = 0.62; 95% CI: 0.37, 0.95) disease,
respectively, adjusting for patient age at diagnosis, clinical and treatment characteristics. No significant variation of
post-BCS radiotherapy was found.
Conclusions: Factors such as region of surgical treatment should not be related to the receipt of standard care
within a publicly-funded health care system. Further investigation is needed to understand the significant geographic
variation present within the province in order to identify appropriate interventions.
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Standard surgical treatment for breast cancer has evolved
over the last three decades leading to significantly im-
proved outcomes [1]. Many women diagnosed with early
stage breast cancer have the option of receiving either
mastectomy or breast-conserving surgery (BCS) followed
by adjuvant radiotherapy. This option is due to results of
several clinical trials and meta-analyses which have dem-
onstrated equivalent survival for women who receive these
two treatment options [2-4]. BCS with radiotherapy is rec-
ommended as the preferred treatment option because* Correspondence: mwinget@stanford.edu
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unless otherwise stated.BCS is a less invasive procedure, provides a better cos-
metic outcome and is associated with less morbidity com-
pared to mastectomy [5]. Research also suggests that
those who receive mastectomy have significantly inferior
body image, poorer sexual function, lower quality of life
and a lower surgical satisfaction rate compared to those
who receive BCS [6-9]. Receipt of BCS has been found to
be associated with patient age and socioeconomic status
in addition to tumor characteristics [10-13].
The receipt of radiotherapy is a vital component of
treatment for women who receive breast-conserving sur-
gery. A recent meta-analysis found that the 15-year breast
cancer mortality risk was reduced by 5.4% (30.5% versus
35.9%) and the 5-year local recurrence risk was reduced
by 19% (7% versus 26%) among women with early stageThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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radiotherapy [14]. Receipt of radiotherapy after BCS has
been found to be associated with patient age and race,
geography, operating surgeon, and patient distance from
radiotherapy facilities [15-17].
The purpose of this study was to: 1) assess the propor-
tion of early stage breast cancer patients surgically
treated with BCS versus mastectomy, 2) assess the pro-
portion of those treated with BCS who subsequently re-
ceive radiotherapy, and 3) explore factors associated
with the treatments received in Alberta, Canada. Alberta
has a publicly-funded health care system, therefore,
assessing variation in care and patient outcomes are im-
portant accountability factors for Alberta Health Services,
the provincial provider of healthcare. Understanding treat-
ment patterns and variation in jurisdictions is useful for
informing potential strengths and issues that may exist
in other similar jurisdictions and possibly dissimilar
jurisdictions.
Methods
All cases of stage I, II or III breast cancer (International
Classification of Diseases for Oncology [ICD-O-3] code
c50 [18]) diagnosed in adult women from 2002 to 2010
who received breast cancer surgery were identified from
the Alberta Cancer Registry. Cases of breast cancer were
excluded if: 1) the cancer was not the first primary
breast cancer diagnosis; 2) if the histology indicated it
was a sarcoma, lymphoma or hematopoietic tumor and,
3) if the patient had another cancer diagnosis within
6 months prior to the breast cancer case, for this may
influence breast cancer treatment decisions. Patient age,
clinical, and treatment information were obtained from
the cancer registry including: date of diagnosis; age at
diagnosis; estrogen and progesterone receptor (ER/PR)
status; cancer stage; type of surgery; geographic region
of surgery; receipt of neo-adjuvant and adjuvant chemo-
therapy; receipt of post-operative radiotherapy; and re-
ceipt of hormone therapy. Cancer stage was determined
using the American Joint Committee on Cancer (AJCC)
5th edition staging rules for years 2002 and 2003 and the
6th edition for years 2004–2010 [19,20]. Geographic re-
gion of surgery was categorized into the five administra-
tive health zones of Alberta. The province of Alberta
consists of an area of 662,000 km2 and has a population
of 3.7 million. Approximately 80% of the population res-
ide in urban areas [21]. Patients diagnosed in 2002 and
2003 who received hormone therapy were classified as
ER/PR positive, while those who did not receive hor-
mone therapy were classified as ER/PR negative, since
estrogen and progesterone receptor data was not col-
lected in these years. If ER/PR status was missing in pa-
tients diagnosed from 2004 to 2010, the case was
assumed to be ER/PR positive (N = 108), since roughly75% of breast cancers in North American are ER/PR
positive [22]. Sensitivity analysis found that this assump-
tion did not affect the study results. The Alberta Cancer
Registry was awarded the highest level of certification by
the North American Association of Central Cancer
Registries in all years of the study for its high level of
completeness and for the timeliness of data collection
and reporting.
Data analyses were performed on two different out-
comes: receipt of BCS and receipt of radiotherapy after
BCS. First, descriptive statistics were calculated for the
demographic, clinical, and treatment characteristics of
the breast cancer patients by receipt of BCS and stage at
diagnosis; Chi-square and Fisher exact tests were used
to determine statistical differences. Log-binomial mul-
tiple regression was then used to calculate stage-specific
relative risk (probability ratio) estimates of receiving
BCS by the following factors: age at diagnosis; geography
of surgery; year of diagnosis; ER/PR status; and neo-
adjuvant chemotherapy status. Interaction between year
of diagnosis and geography of surgery was also assessed
through an interaction model; interaction effects were
displayed separately from the main effect model strati-
fied by year of diagnosis and geography of surgery to en-
able easier interpretation (shown in Additional file 1:
Tables S1-1, S1-2 and S1-3). The log-binomial regression
method provides relative risk estimates as a measure of
association using binary outcome data which are easier
to interpret than odds ratios obtained from the more
traditional logistic regression model.
The same data analysis procedures described above were
used to assess associations with receipt of radiotherapy
after BCS with slight modifications. For this outcome, hor-
mone therapy was combined with ER/PR status as a single
variable to assess whether ER/PR positive patients who
did not receive hormone therapy were also less likely to
receive radiotherapy after BCS. Secondly, adjuvant
chemotherapy status was included in the regression
model because receipt of adjuvant chemotherapy could
affect whether a patient received post-surgical radiation.
Log-binomial regression with the COPY method was
used [23].
All statistical analyses were performed using SAS
statistical software version 9.3 (SAS Institute, Cary,
NC, USA). This study received ethics approval from
the Health Research Ethics Board of the University of
Alberta.
Results
There were 14 933 patients diagnosed with stage I, II or
III first-ever breast cancer diagnosed in Alberta from
2002 to 2010, excluding patients with non-solid tumors
and those who had another cancer diagnosis within
6 months prior to their breast cancer diagnosis. Patients
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those who received an unknown or other surgery type
were also excluded (6 patients). The final cohort consists
of 14 646 patients.
Patient age, clinical and treatment characteristics and
their associations with receipt of BCS are shown in
Table 1. A total of 6 458 patients (44%) received BCS.
The proportion of patients treated with BCS was 57%,
37% and 17%, for stage I, II and III cancers, respectively,
and was relatively constant over the study period. Re-
gardless of stage, the proportion of patients treated with
BCS was highest when surgery occurred in an urban
center (Edmonton or Calgary), when treatment with
neo-adjuvant chemotherapy was not utilized, and when
patients were less than 70 years old.
Table 2 displays the characteristics of breast cancer pa-
tients by geographic region of surgery. Most patients re-
ceived surgery in one of the two urban centers, Calgary
(38%) or Edmonton (43%). Patients differed to some ex-




Overall 4067 (57) 7091
Age at diagnosis P < 0.001
<50 880 (58) 1509
50-59 1171 (63) 1853
60-69 1051 (58) 1801
70-79 697 (50) 1394
≥80 268 (50) 534
Geography of surgery P < 0.001
Calgary 1637 (62) 2659
South 289 (50) 577
Central 178 (39) 461
Edmonton 1849 (58) 3180
North 114 (53) 214
Year of diagnosis P = 0.09
2002-2004 1277 (56) 2296
2005-2007 1315 (58) 2284
2008-2010 1475 (59) 2511
ER/PR status P = 0.04
Positive 3407 (58) 5885
Negative 660 (55) 1206
Neo-adjuvant chemotherapy P < 0.001
Not received 4060 (58) 7054
Received 7 (19) 37
1P values reflect Chi square tests of association for BCS versus mastectomy.
2The denominator for each percentage is the number of patients in the adjacent rogeography of surgery. The percentage of patients under
age 60 who received surgery in Southern or Central
Alberta was 45-47% whereas patients under age 60 com-
prised 50-55% of the patients in the other regions. The
percentage of patients with ER/PR negative disease
ranged from a low of 16% in Calgary to a high of 25% in
the North. Patients who received surgery in Northern
Alberta, were also more likely to have stage II/III cancers
(60%), and to receive neo-adjuvant (8%) and adjuvant
chemotherapy (43%), compared to patients from other
regions.
The stage-specific adjusted relative risk estimates of
receiving BCS are displayed in Table 3. For all stages, re-
ceipt of BCS was associated with age less than 70 years
at diagnosis and not receiving neo-adjuvant chemother-
apy treatment. Substantial variation in the receipt of BCS
was found by geographic area of surgery for stage I and II
disease. The adjusted relative risk of BCS was highest in
Calgary and lowest in Central Alberta for all disease
stages. Relative to surgeries performed in Calgary, thoseo received breast conserving surgery (BCS)1
Stage II Stage III
BCS Total BCS Total
N (%)2 N N (%)2 N
2060 (37) 5619 331 (17) 1936
P < 0.001 P = 0.018
656 (40) 1638 112 (18) 628
585 (41) 1417 101 (20) 505
430 (38) 1144 66 (18) 370
248 (29) 861 27 (11) 251
141 (25) 559 25 (14) 182
P < 0.001 P = 0.20
901 (42) 2156 139 (19) 739
145 (30) 490 25 (17) 146
112 (24) 473 17 (11) 157
832 (37) 2258 134 (17) 804
70 (29) 242 16 (18) 90
P = 0.39 P = 0.85
632 (36) 1767 86 (16) 522
668 (36) 1842 124 (18) 701
760 (38) 2010 121 (17) 713
P = 0.22 P = 0.15
1686 (37) 4551 266 (18) 1495
374 (35) 1068 65 (15) 441
P < 0.001 P < 0.001
1994 (37) 5336 303 (20) 1523
66 (23) 283 28 (7) 413
w for the same stage of disease.
Table 2 Characteristics of breast cancer patients by geographic region of surgery
Geography of surgery
Calgary South Central Edmonton North
N (%) N (%) N (%) N (%) N (%)
Total 5554 (38) 1213 (8) 1091 (7) 6242 (43) 546 (4)
Surgical treatment
Mastectomy 2877 (52) 754 (62) 784 (72) 3427 (55) 346 (63)
BCS 2677 (48) 459 (38) 307 (28) 2815 (45) 200 (37)
With Radiation 2381 (89) 369 (80) 253 (82) 2492 (89) 168 (84)
Without Radiation 296 (11) 90 (20) 54 (18) 323 (11) 32 (16)
Stage
I 2659 (48) 577 (48) 461 (42) 3180 (51) 214 (39)
II 2156 (29) 490 (40) 473 (43) 2258 (36) 242 (44)
III 739 (13) 146 (12) 157 (14) 804 (13) 90 (16)
Age at diagnosis
<50 1597 (29) 244 (20) 256 (23) 1522 (24) 156 (29)
50-59 1471 (26) 298 (25) 265 (24) 1603 (26) 138 (25)
60-69 1170 (21) 284 (23) 247 (23) 1487 (24) 127 (23)
70-79 875 (16) 235 (19) 203 (19) 1103 (18) 90 (16)
≥80 441 (8) 152 (13) 120 (11) 527 (8) 35 (6)
Year of diagnosis
2002-2004 1761 (32) 390 (32) 365 (33) 1900 (30) 169 (31)
2005-2007 1824 (33) 405 (33) 354 (32) 2052 (33) 192 (35)
2008-2010 1969 (35) 418 (34) 372 (34) 2290 (37) 185 (34)
ER/PR status
Positive 4659 (84) 975 (80) 846 (76) 5044 (81) 407 (75)
Negative 895 (16) 238 (20) 245 (22) 1198 (19) 139 (25)
Neo-adjuvant chemotherapy
Not Received 5322 (96) 1187 (98) 1035 (95) 5865 (94) 504 (92)
Received 232 (4) 26 (2) 56 (5) 377 (6) 42 (8)
Adjuvant chemotherapy
Not Received 3460 (62) 825 (68) 657 (60) 3962 (63) 312 (57)
Received 2094 (38) 388 (32) 434 (40) 2280 (37) 234 (43)
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to be BCS for stage I (RR = 0.65; 95% CI: 0.57, 0.72), II
(RR = 0.58; 95% CI: 0.49, 0.68), and III (RR = 0.62; 95% CI:
0.37, 0.95) disease, respectively, adjusting for age at diag-
nosis, year of diagnosis, ER/PR status and receipt of neo-
adjuvant chemotherapy. In the most recent time period
(2008–2010), among stage I and II patients less than
70 years of age, 1601 (48%) patients received mastectomy,
while 1707 (52%) patients received BCS; 578 (46%), 152
(57%), 144 (67%), 650 (45%) and 68 (58%) patients from
Calgary, Southern, Central, Edmonton and Northern
Alberta received mastectomy, as opposed to BCS. BCS
uptake among stage I and II patients increased signifi-
cantly over the study period in Edmonton (P < 0.05),decreased among stage II patients in Central Alberta
(P < 0.05) and remained fairly steady in the other re-
gions and in stage III patients over the study period
(Additional file 1: Tables S1–1, S1–2 and S1–3).
Table 4 displays the relationship between patient age,
clinical, and treatment characteristics and their associa-
tions with receipt of radiotherapy in the subgroup of pa-
tients treated with BCS. Of the 6 458 patients treated
with BCS, 88% subsequently received adjuvant radiother-
apy. The proportion of patients that received radiother-
apy after BCS was 89%, 86%, and 83% for stage I, II and
III breast cancers, respectively. Receipt of radiotherapy
was highest among patients with ER/PR negative and
ER/PR positive cancers treated with hormone therapy,
Table 3 Adjusted1 relative risk estimates of receiving BCS rather than mastectomy
Adjusted1 relative risk estimates (95% confidence intervals)
Stage I Stage II Stage III
Age at diagnosis P < 0.001 P < 0.001 P < 0.001
<50 1.00 1.00 1.00
50-59 1.08 (1.02, 1.14) 1.03 (0.95, 1.13) 1.10 (0.86, 1.39)
60-69 1.01 (0.95, 1.07) 0.94 (0.86, 1.03) 0.95 (0.72, 1.24)
70-79 0.87 (0.81, 0.93) 0.71 (0.63, 0.80) 0.53 (0.35, 0.77)
≥80 0.87 (0.79, 0.95) 0.62 (0.53, 0.73) 0.63 (0.41, 0.92)
Geography of surgery P < 0.001 P < 0.001 P = 0.30
Calgary 1.00 1.00 1.00
South 0.83 (0.76, 0.90) 0.74 (0.63, 0.85) 0.92 (0.61, 1.32)
Central 0.65 (0.57, 0.72) 0.58 (0.49, 0.68) 0.62 (0.37, 0.95)
Edmonton 0.96 (0.92, 1.00) 0.91 (0.85, 0.98) 0.95 (0.77, 1.18)
North 0.88 (0.77, 0.99) 0.72 (0.58, 0.88) 0.95 (0.57, 1.45)
Year of diagnosis P = 0.24 P = 0.40 P = 0.99
2002-2004 1.00 1.00 1.00
2005-2007 1.02 (0.97, 1.08) 1.02 (0.94, 1.11) 1.02 (0.80, 1.31)
2008-2010 1.04 (0.99, 1.09) 1.06 (0.97, 1.15) 1.02 (0.79, 1.31)
ER/PR status P = 0.11 P = 0.34 P = 0.44
Positive 1.00 1.00 1.00
Negative 0.96 (0.90, 1.01) 0.96 (0.88, 1.04) 0.91 (0.70, 1.15)
Neo-adjuvant chemotherapy P < 0.001 P < 0.001 P < 0.001
Not Received 1.00 1.00 1.00
Received 0.32 (0.15, 0.57) 0.57 (0.45, 0.70) 0.31 (0.21, 0.45)
1Adjusted for all variables in the table.
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or Calgary), those who received adjuvant chemotherapy
and in those younger than 80 years of age, regardless of
the cancer stage. Patients aged 80 years or older at diag-
nosis were at least 40% less likely to receive radiation
after BCS compared to patients aged 70–79 years at
diagnosis in all disease stages.
Table 5 displays the stage-specific adjusted relative risk
estimates of receiving radiotherapy after BCS. Patients
aged 80 years or older were 51%, 47% and 36% less likely
to be treated with adjuvant radiotherapy for stage I (RR
= 0.49; 95% CI: 0.43, 0.56), stage II (RR = 0.53; 95% CI:
0.43, 0.64), and stage III (RR = 0.64; 95% CI: 0.34, 1.05)
cancers, respectively, compared to those less than 50
years of age, adjusting for age at diagnosis, year of diag-
nosis, ER/PR status and hormone therapy, neo-adjuvant
chemotherapy and adjuvant chemotherapy. Patients who
were ER/PR positive but did not receive hormone ther-
apy were 14%, 41% and 65% less likely to receive radi-
ation after BCS in stage I (RR = 0.86; 95% CI: 0.83, 0.89),
II (RR = 0.59; 95% CI: 0.49, 0.68), and III (RR = 0.35; 95%
CI: 0.16, 0.60) cancers, respectively, than those who were
ER/PR positive and received hormone therapy. Treatmentwith adjuvant chemotherapy was also associated with
receipt of radiotherapy, after adjustment, in stage II
(RR = 1.08; 95% CI: 1.05, 1.13) and III (RR = 1.37; 95%
CI: 1.14, 1.84) cancers, compared to not being treated
with adjuvant chemotherapy. No significant geograph-
ical variation of post-BCS radiotherapy receipt was
found.
Discussion
In this study, 44% of early stage breast cancer patients
diagnosed from 2002 to 2010 in Alberta received breast
conserving surgery, as opposed to mastectomy (57%,
37% and 17% of stage I, II and III patients, respectively).
Similar population-based results have been reported in
the Netherlands, where 48% of patients diagnosed be-
tween 2003 and 2006 received BCS (63%, 41% and 19%
of stage I, II and III patients, respectively) [24]. BCS re-
ceipt among patients in the United States is higher, with
estimates ranging from 50% to 70% [17,25-28]. Within
Canada, estimates range from 74% in Quebec to 31%
and 35% in Newfoundland and Saskatchewan, respect-
ively [29]. Tyldesley et al. (2003) have estimated that in
North America, 70% of all breast cancers are eligible for
Table 4 Characteristics of breast cancer patients who received radiotherapy treatment after breast conserving surgery1













N (%)2 N N (%)2 N N (%)2 N
Overall 3607 (89) 4067 1780 (86) 2060 276 (83) 331
Age at diagnosis P < 0.001 P < 0.001 P < 0.001
<50 821 (93) 880 599 (91) 656 93 (83) 112
50-59 1096 (94) 1171 521 (89) 585 94 (93) 101
60-69 971 (92) 1051 392 (91) 430 57 (86) 66
70-79 601 (86) 697 211 (85) 248 23 (85) 27
≥80 118 (44) 268 57 (40) 141 9 (36) 25
Geography of surgery P < 0.001 P = 0.001 P = 0.70
Calgary 1485 (91) 1637 783 (87) 901 113 (81) 139
South 236 (82) 289 113 (78) 145 20 (80) 25
Central 149 (84) 178 90 (80) 112 14 (82) 17
Edmonton 1640 (89) 1849 738 (89) 832 114 (85) 134
North 97 (85) 114 56 (80) 70 15 (94) 16
Year of diagnosis P = 0.06 P = 0.01 P = 0.10
2002 - 2004 1148 (90) 1277 565 (89) 632 78 (91) 86
2005 - 2007 1145 (87) 1315 560 (84) 668 101 (81) 124
2008 - 2010 1314 (89) 1475 655 (86) 760 97 (80) 121
ER/PR Status & Hormone
therapy
P < 0.001 P < 0.001 P < 0.001
ER/PR positive & received
hormone
2337 (93) 2514 1399 (92) 1516 213 (90) 237
ER/PR positive & no hormone 685 (77) 893 79 (46) 170 7 (24) 29
ER/PR negative 585 (89) 660 302 (81) 374 56 (86) 65
Neo-adjuvant chemotherapy P = 0.57 P = 0.36 P = 0.10
Not received 3601 (89) 4060 1720 (86) 1994 256 (84) 303
Received 6 (86) 7 60 (91) 66 20 (71) 28
Adjuvant chemotherapy P < 0.001 P < 0.001 P < 0.001
Not received 2951 (87) 3381 617 (75) 823 52 (55) 95
Received 656 (96) 686 1163 (94) 1237 224 (95) 236
1P values reflect Chi square tests of association for BCS versus mastectomy.
2The denominator for each percentage is the number of patients who received breast conserving surgery in the adjacent row for the same stage of disease.
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to mastectomy [30]. The great variation present within
and between countries, however, suggests that there is
not a consensus on standard practice.
In a publicly-funded health care system, factors such
as region of residence should not be related to the re-
ceipt of standard treatment. This study found significant
variation in surgical breast cancer treatment received by
geography in Alberta, while finding no apparent geo-
graphical variation in the receipt of post-BCS radiother-
apy. The consistent finding across disease stage that the
highest rate of mastectomy is in Central Alberta is rathersurprising. Poor access to radiation therapy has been as-
sociated with low BCS rates in other studies [25,27,28],
and may partially explain the geographic variation we
found. At the time of this study, however, patients in
Central Alberta did not have worse access to radiation
facilities compared to those in Northern or Southern
Alberta; in fact, many patients in Central Alberta live
significantly closer to radiation facilities than those in
Southern or Northern Alberta, suggesting better access.
While poor access to radiation therapy may partially
explain the lower BCS rates in Northern and Southern
Alberta which have lower population densities than
Table 5 Adjusted1 relative risk estimates of receiving radiotherapy treatment after breast conserving surgery
Adjusted1 relative risk estimates (95% confidence interval)
Stage I Stage II Stage III
Age at diagnosis P < 0.001 P < 0.001 P = 0.37
<50 1.00 1.00 1.00
50-59 1.00 (0.98, 1.02) 0.99 (0.96, 1.02) 1.02 (0.96, 1.10)
60-69 0.99 (0.96, 1.01) 1.02 (0.99, 1.04) 1.02 (0.92, 1.10)
70-79 0.94 (0.91, 0.97) 1.01 (0.96, 1.04) 1.03 (0.90, 1.11)
≥80 0.49 (0.43, 0.56) 0.53 (0.43, 0.64) 0.64 (0.34, 1.05)
Geography of surgery P = 0.09 P = 0.07 P = 0.87
Calgary 1.00 1.00 1.00
South 0.96 (0.91, 1.00) 0.94 (0.86, 1.00) 1.03 (0.89, 1.11)
Central 0.96 (0.91, 1.01) 0.97 (0.90, 1.01) 1.03 (0.86, 1.11)
Edmonton 0.99 (0.98, 1.01) 1.00 (0.98, 1.03) 1.03 (0.97, 1.10)
North 0.95 (0.88, 1.00) 0.92 (0.81, 1.01) 1.03 (0.82, 1.12)
Year of diagnosis P = 0.25 P = 0.15 P = 0.96
2002 - 2004 1.00 1.00 1.00
2005 - 2007 0.99 (0.97, 1.01) 0.97 (0.94, 1.00) 1.00 (0.94, 1.06)
2008 - 2010 1.00 (0.98, 1.02) 0.98 (0.96, 1.01) 0.99 (0.92, 1.06)
ER/PR Status & Hormone therapy P < 0.001 P < 0.001 P < 0.001
ER/PR positive & received hormone 1.00 1.00 1.00
ER/PR positive & no hormone 0.86 (0.83, 0.89) 0.59 (0.49, 0.68) 0.35 (0.16, 0.60)
ER/PR negative 0.94 (0.91, 0.97) 0.89 (0.84, 0.93) 0.95 (0.85, 1.02)
Neo-adjuvant chemotherapy P = 0.33 P = 0.04 P = 0.86
Not received 1.00 1.00 1.00
Received 0.89 (0.52, 1.05) 1.10 (1.00, 1.14) 1.03 (0.72, 1.47)
Adjuvant chemotherapy P = 0.62 P < 0.001 P < 0.001
Not received 1.00 1.00 1.00
Received 1.01 (0.98, 1.02) 1.08 (1.05, 1.13) 1.37 (1.14, 1.84)
1Adjusted for all variables in the table.
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gests that distance to radiotherapy is not the only im-
portant factor influencing choice of surgical treatment.
Geographic variation in the receipt of breast conserving
surgery has also been found in other health care systems,
including in the Netherlands [24] and in Switzerland [31].
The results from both of these studies also suggest that
distance to radiotherapy is not the primary reason for the
observed geographic variation; the authors suggest instead
that provider-related factors are a more likely explanation.
We make the same hypothesis for the present results in
Alberta, factors such as provider volume and preferences,
which have been associated with patient surgery type re-
ceived, influence the receipt of BCS by breast cancer pa-
tients differentially across the province [32,33]. Publicly-
funded health care systems do not ensure equity of care
by region, and effort is needed to further investigate
and address these inequities. Since 2010, Alberta HealthServices has increased the number of sites which provide
radiotherapy across the province. Investigation into how
this affects geographical variation of BCS receipt in the fu-
ture will help elucidate the impact of access to radiation
compared to other factors.
Of patients who received BCS, 88% subsequently re-
ceived radiation therapy. In comparison, it can be esti-
mated that around 80% of patients from the United
States receive post-BCS radiation [15,17,27], and it has
been reported that 99% of patients in the Netherlands
received this treatment in 2008, rising from 87% in 1997
[34]. These estimates suggest that physicians collectively
recognize the importance of radiotherapy treatment after
BCS. We found that the proportion of patients who re-
ceived post-BCS radiotherapy dropped dramatically with
age greater than 80 years, however. This can be attributed
to unclear advantages of radiotherapy in this population
when life expectancy, potential toxicity and comorbidities
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discussion as to whether or not postoperative radiotherapy
can be reasonably omitted in some women over the age of
70 with low-risk breast cancer [35-37].
A great strength of this study is that it is population-
based and thus contains the entire population of interest
in Alberta over an eight year period. In practice, treatment
choices are made based on various factors including
patient preference, feasibility (e.g. distance and access to
transportation), and the presence of comorbidities. It is,
therefore, of clinical interest to investigate treatments re-
ceived in a population based series of patients. In addition
to this, the data source used is known for being very
complete and accurate, as the Alberta Cancer Registry
captures 99.9% of cancer cases. A limitation of the study,
however, was our inability to assess patient preferences
and contraindications for breast-conserving surgery due
to the nature of the data source. For example, there may
be residual confounding of the BCS geography association
by tumor size beyond that explained by stage as patients
with very large tumors may be more likely to reside in
rural areas. We were also not able to account for con-
founding by economic status, race or surgeon preference,
all of which may explain some of the geographic variation
seen. Further interpretation of the BCS receipt results
could have been achieved if a subgroup analysis had been
performed, in which patients with contraindications for
BCS, such as those with very large tumors, were excluded.
Conclusions
This study found significant geographic variation in BCS
receipt and consistently high rates of adjuvant radiation
in those who received BCS across the province. Overall,
treatment patterns did not change between 2002 and
2010, although some area-specific trends were found.
Further investigation is needed to understand the low
rates of breast-conserving surgery in certain parts of the
province, such as Central Alberta, compared to other
parts in order to identify appropriate interventions. This
study provides strong baseline information on variation
in rates of BCS and subsequent radiation therapy in Al-
berta over an eight year time period which will be useful
for evaluating the effectiveness of interventions that are
implemented in the future.Additional file
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